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ADAM = a disintegrin and metalloproteinase; ADAMTS = a disintegrin and metalloproteinase with thrombospondin motifs; CRD = cysteine-rich
domain; CS = chondroitin sulphate; CUB = complement C1r/C1s, Uegf (EGF-related sea urchin protein) and BMP-1 (bone morphogenic protein-1);
ECM = extracellular matrix; EGF = epidermal growth factor; IGD = interglobular domain; IL = interleukin; MMP = matrix metalloproteinase; OA =
osteoarthritis; PLAC = protease and lacunin; TIMP = tissue inhibitor of metalloproteinases; TSR = thrombospondin type 1-like repeat; VEGF = vas-
cular endothelial growth factor; vWF = von Willebrand factor.
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Abstract
Members of the ADAMTS (a disintegrin and metalloproteinase with
thrombospondin motifs) family are known to influence develop-
ment, angiogenesis, coagulation and progression of arthritis. As
proteinases their substrates include the von Willebrand factor
precursor and extracellular matrix components such as pro-
collagen, hyalectans (hyaluronan-binding proteoglycans including
aggrecan), decorin, fibromodulin and cartilage oligomeric matrix
protein. ADAMTS levels and activities are regulated at multiple
levels through the control of gene expression, mRNA splicing,
protein processing and inhibition by TIMP (tissue inhibitor of
metalloproteinases). A recent screen of human cartilage has
shown that multiple members of the ADAMTS family may be
important in connective tissue homeostasis and pathology.
Introduction
ADAMTS (a disintegrin and metalloproteinase with thrombo-
spondin motifs) proteinases are a group of secreted enzymes;
many of them have been found to be expressed in cartilage [1].
Functional investigations of these enzymes have largely been
limited to a few specific members, particularly ADAMTS-4,
which has been implicated in the progression of arthritis [2,3].
The purpose of this review is to summarise the structure,
function and regulation of the entire ADAMTS group of
proteinases and to emphasise areas of potential relevance with
regard to the homeostasis and pathology of connective tissues.
ADAMTS evolution and structure
ADAMTS proteinases were first described in mice by Kuno
and colleagues in 1997 [4] and have subsequently been
identified in mammals and Caenorhabditis elegans. They form
part of subfamily B (adamalysin subfamily), family M12, in clan
MA of the metallopeptidases, as defined in the MEROPS
database [5,6] and are structurally and evolutionarily related
to the ADAM (a disintegrin and metalloproteinase; also part
of the adamalysin subfamily) enzymes and, more distantly, the
matrix metalloproteinase (MMP; family M10 in clan MA)
enzymes. A comparison of the minimal characteristic domain
organisation of these groups of proteinases is shown in
Fig. 1.
Nineteen distinct human ADAMTS gene products have been
identified. A nearest-neighbour dendrogram constructed
(using ClustalW 1.7 [7]) from sequence alignments of the
entire protein indicates that human ADAMTS proteins can be
broadly divided into four subdivisions, which also seem to
share structural characteristics and activities (see Fig. 2 and
below). A dendrogram constructed from the sequence align-
ment of the catalytic domains was almost identical, which
implies that the catalytic and ancillary domains evolved
together (data not shown). The first of the divisions, consis-
ting of ADAMTS-1, -4, -5, -8, -9, -15 and -20, subdivides into
two further groups, one composed of ADAMTS-9 and -20
and the other of ADAMTS-1, -4, -5, -8 and -15. A second,
well-defined, subgroup contains ADAMTS-2, -3 and -14.
ADAMTS-13 stands alone, and the remaining ADAMTS
members form a loosely defined subgroup within which
members are further divided into four pairs (ADAMTS-19 and
-17, ADAMTS-18 and -16, ADAMTS-12 and -7, and
ADAMTS-10 and -6) sharing structural features. A detailed
study of the phylogenetic relationship of the ADAMTS family
members has recently been published [8].
ADAMTS domain structure
The signal sequence of ADAMTS proteins is followed by a
pro-region of varying length, but which is unusually short in
ADAMTS-13. The pro-domain of all ADAMTS proteinases
contains at least one furin cleavage consensus motif; it is
therefore generally believed that the zymogen forms of
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ADAMTS proteinases are cleaved intracellularly and that
secreted proteins are in the mature form. This mechanism of
maturation is supported by studies of ADAMTS-4, which
identify an N terminus of F213ASLS in supernatants
conditioned by cells transfected with ADAMTS-4, suggesting
that the prodomain is efficiently removed in vivo [9]. The
same study also demonstrated that purified proADAMTS-4
could be cleaved by recombinant furin in cell-free
experiments. Furin has recently been shown to interact with
the pro-form of ADAMTS-4 and to co-localise within the
trans-Golgi network [10]. Using furin inhibitors and RNA
interference techniques, the removal of the pro-domain was
inhibited without affecting secretion, demonstrating an
important role for furin in intracellular processing [10]. The
same study also revealed the presence of furin-independent
pro-domain processing pathways in some cells.
The catalytic domains of ADAMTS proteinases share a high
degree of similarity and contain the zinc-binding sequence
HEXXHXXGXXH, in which the catalytic zinc is coordinated
by the three histidine residues. This arrangement is facilitated
by the conserved glycine, which permits a tight hairpin loop
and enables the third histidine to occupy its correct position
[11,12]. As in all MMPs and adamalysins, the zinc-binding
sequence is followed at a short distance C-terminally by a
conserved methionine residue, an active-site arrangement
that has been termed ‘metzincin-type’. This methionine
constitutes the ‘Met-turn’, a tight turn arranged as a right-
handed screw that seems to serve an important function in
the structure of the active site [11].
The catalytic domain is followed by a region with 25 to 45%
identity to the snake venom disintegrins, although it does not
contain the cysteine arrangement of the latter [13]. This
domain has therefore been termed disintegrin-like, though
there is currently no published evidence that this ADAMTS
domain interacts with integrins.
Unlike ADAM proteins, ADAMTS proteinases possess a well-
conserved thrombospondin type 1-like repeat (TSR), homolo-
gous to the type I repeats of thrombospondins 1 and 2 [14],
between the disintegrin-like and cysteine-rich domain (CRD).
By analogy to thrombospondins 1 and 2 [15], the central
TSR of ADAMTS proteinases is believed to function as a
sulphated glycosaminoglycan-binding domain. The
independently expressed central TSR of murine ADAMTS-1
required 0.46 to 0.66 M NaCl for elution from a heparin
affinity column, indicating that this motif forms a functional
heparin-binding unit [16].
The CRD is a well-conserved cysteine-rich sequence
containing 10 cysteine residues. In contrast to ADAM
proteins, in which the CRD is followed by epidermal growth
factor (EGF)-like repeats, a transmembrane domain and C-
terminal cytosolic region, all ADAMTS proteinases possess
instead a cysteine-free ‘spacer’ region. This domain varies in
length and contains several conserved hydrophobic residues
in the N-terminal portion and an extremely variable C-terminal
portion. The expression of various domain-deletion constructs
of murine ADAMTS-1 revealed the CRD-spacer sequence as
a functional extracellular matrix (ECM)-binding domain [16].
This role was supported by investigation of C-terminally
processed forms of human ADAMTS-4, which, in
combination with a deletion construct lacking the CRD-
spacer sequence, indicated that these domains also bind to
both heparin and the glycosaminoglycans of aggrecan
Figure 1
Schematic representation of the minimal domain organisation of matrix metalloproteinase (MMP), ADAM (a disintegrin and metalloproteinase) and
ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs; for example ADAMTS-4) proteinases. Note that most MMPs possess
additional C-terminal extensions containing domains such as hemopexin-like and fibronectin type II domains. ADAMTS possess from 0 to 14
additional thrombospondin type 1-like repeat (TSR)-like motifs C-terminal to the spacer domain. EGF, epidermal growth factor; TM, transmembrane.162
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(predominantly keratan and chondroitin sulphates) [9]. Three
putative heparin-binding sequences were identified within the
CRD-spacer sequence of ADAMTS-4, one within the CRD
and two within the spacer, and peptides corresponding to
these sequences were shown to inhibit the binding of
ADAMTS-4 to heparin [9].
With the exception of ADAMTS-4, which terminates after the
spacer region, all ADAMTS proteinases possess between 1
and 14 TSRs C-terminal to the spacer region (Fig. 2). The
sequence of these additional TSRs is more variable between
the ADAMTS proteinases than is the central TSR, but the
independent expression of the C-terminal TSRs of murine
ADAMTS-1 has indicated that these motifs can form
functional heparin-binding units [16]. The TSRs of the C-
terminal region are arranged in one, two or three tandem
arrays. Between arrays is either a short linker sequence
(ADAMTS-9 and ADAMTS-20) or a mucin-like domain
(ADAMTS-7 and ADAMTS-12) [17].
Four additional types of module have been described in the
ADAMTS group and all are present C-terminal to the TSR
arrays. ADAMTS-9 and -20 contain a unique module, also
found in the C. elegans ADAMTS GON-1, containing 10
conserved cysteine residues [18]. Several ADAMTS
proteinases (-6, -7, -10, -12, -16, -17, -18 and -19) possess a
PLAC (protease and lacunin) domain containing six
conserved cysteine residues, which is found in some pro-
protein convertases [19]. A C-terminal extension containing a
unique embedded PLAC domain is present in ADAMTS-2, -3
and -14. Finally, CUB (complement C1r/C1s, Uegf (EGF-
related sea urchin protein) and BMP-1 (bone morphogenic
protein-1)) domains are present at the C terminus of
ADAMTS-13 [20]. This domain is also present in
Figure 2
Schematic representation of the structural and evolutionary relationship of the 19 human ADAMTS (a disintegrin and metalloproteinase with
thrombospondin motifs) gene products. The dendrogram was calculated with ClustalW 1.7 [7]. The structural representation of ADAMTS proteins
was adapted from [81]. Where applicable the long form of splice variants is shown (see the text). CS, chondroitin sulphate; CUB, complement
C1r/C1s, Uegf (epidermal growth factor-related sea urchin protein) and BMP-1 (bone morphogenic protein-1); PLAC, protease and lacunin; TSR,
thrombospondin I-like repeat; vWFCP, von Willebrand factor-cleaving protease.163
spermadhesins, tumour necrosis factor-stimulated gene-6
and the complement proteins C1r, C1s and mannan-binding
lectin-associated serine proteinases, among others [21], and
there is evidence to suggest that these domains mediate
protein–protein interactions with other CUB domain-
containing proteins [22,23].
Functions of ADAMTS proteins
Hyalectanases: ADAMTS-1, -4, -5, -8, -9, -15 and -20
ADAMTS-1, -4, -5, -8 -9 and -15 cleave the hyalectan
(hyaluronan-binding proteoglycan) aggrecan between a
glutamate in the P1 pocket and small aliphatic residues in P1′
(using the terminology of Schechter and Berger [24]), an
activity that has previously been identified and termed
‘aggrecanase’ [25]. Several of these ADAMTS proteinases
also cleave the related hyalectan versican at analogous sites
and ADAMTS-4 has been demonstrated to cleave a further
hyalectan, brevican [26]. These ADAMTS proteinases may
therefore be termed ‘hyalectanases’. ADAMTS-4 has recently
been shown to cleave COMP (cartilage oligomeric matrix
protein) as well as fibromodulin and decorin, indicating that
this subgroup of proteinases is not restricted to the cleavage
of proteglycans and might have a wider proteolytic spectrum
[27]. There are no published reports of hyalectanase activity
for ADAMTS-20, but the catalytic domain of this proteinase
has been demonstrated to be proteolytically active [28].
Although aggrecan is also processed by additional
proteinases, aggrecanase-mediated cleavage is a charac-
teristic event in the catabolism of cartilage aggrecan in the
arthritides [29-31]. The potential importance of aggrecanase-
mediated degradation of aggrecan in cartilage, particularly
with regard to the development of arthritis, is highlighted by
the report that aggrecan protects collagen fibrils from
degradation by collagenases [32]. Aggrecanase-mediated
cleavages of aggrecan and versican have also been reported
to occur in the tensile regions of tendon, suggesting that
such activities might be important in the homeostasis of this
tissue [33].
The involvement of ADAMTS proteinases in connective tissue
turnover has been demonstrated using both cleavage-
epitope-specific antibodies and inhibitors that exclude the
involvement of other proteinases, particularly the MMPs
[3,32]. ADAMTS-4 and -5 have been implicated as the
aggrecanases involved in aggrecan degradation in
osteoarthritis (OA) on the basis of mRNA and protein
expression [3]. Investigations into the relative contributions of
ADAMTS-4 and -5 to the aggrecanase-mediated degradation
of cartilage aggrecan in arthritis models have recently been
conducted in mice with the use of catalytic domain knockouts
of each gene [34-36]. Both ADAMTS-4 and -5 knockout
mice were phenotypically normal and indistinguishable from
wild-type littermates, indicating that each enzyme was
dispensable for normal development [34-36]. In a surgically
induced OA model there was a significant reduction in the
severity of induced OA in ADAMTS-5 knockout mice but no
difference in progression or severity in ADAMTS-4 knockout
mice [34,35]. Similarly, in a model of inflammatory arthritis,
ADAMTS-5, but not ADAMTS-4, knockout mice were
protected against aggrecan loss [36]. Furthermore,
aggrecanase activity was inducible in articular cartilage
explants from wild-type and ADAMTS-4 knockout mice but
not from ADAMTS-5 knockout littermates [34-36]. Together
these studies suggest that, at least in these mouse models,
ADAMTS-5 is primarily responsible for the increased
aggrecanase activity.
In addition to proteoglycan cleavage, members of this
subgroup may also regulate angiogenesis. Vascularisation is
a feature of both chronic tendon pathology [37] and arthritis
[38], and specific ADAMTS proteins may have a role in its
regulation. ADAMTS-1 and -8 possess a potent angio-
inhibitory activity, suppressing both fibroblast growth factor-2
and vascular endothelial growth factor (VEGF)-mediated
angiogenic effects on endothelial cells but not on smooth
muscle cells or fibroblasts [39]. An upregulation of ADAMTS-
4 mRNA expression has also been reported in an in vitro
model of angiogenesis [40]. ADAMTS-1 has been shown to
interact with VEGF165 but does not cleave the growth factor,
suggesting that the inhibitory effect is brought about by
sequestering VEGF from its cell receptor [41]. By analogy to
the thrombospondins, the angioinhibitory activity might be
assumed to be mediated through the TSR motifs [42], but an
ADAMTS-1 C-terminal construct consisting of the central
TSR, CRD, spacer region and C-terminal TSRs was an
ineffective inhibitor in a functional angiogenesis assay [43].
Furthermore, an ADAMTS-1 active site mutant displayed no
angioinhibitory activity [43], therefore suggesting that both
the metalloproteinase and ancillary domains are necessary in
bringing about the angioinhibitory effects.
There is increasing evidence that members of this ADAMTS
subgroup have roles in development. The C. elegans
ADAMTS, GON-1, which is most closely related to ADAMTS-
9 and -20, is involved in cell migration during the
development of the gonad [18,44,45]. Studies in mice
indicate that ADAMTS-20 is required for the migration of
melanoblasts during embryogenesis, and that mutation of
ADAMTS-20 causes a white-spotting mutation, Belted [46].
ADAMTS-1-null mice display several developmental abnor-
malities, primarily within the urogenital systems, affecting
normal growth, organ morphology and function, and female
fertility [47,48]. A role for ADAMTS-1 in ovulation has been
inferred from studies in rats [49], mice [50] and horses [51],
which indicate that upregulation of ADAMTS-1 mRNA
correlates temporally with the appearance of ADAMTS-
cleaved versican within the ECM of the cumulus oocyte
complex [52]. The active form of ADAMTS-4 (but not
ADAMTS-5) has been reported to co-localise with ADAMTS-
mediated aggrecan cleavage in developing long bones in the
rat, implying that ADAMTS-4 mediates the developmental
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turnover of aggrecan during long bone formation [53].
However, an ADAMTS-4 knockout mouse showed no signs
of skeletal abnormalities despite evidence of ADAMTS-4
expression and activity in the growth plates of wild-type
mice [34].
Procollagen N-propeptidases: ADAMTS-2, -3 and -14
ADAMTS-2 cleaves the amino peptides of type I, type II and
type III procollagens [54,55], and genetic analysis has
indicated that mutations in the ADAMTS2 gene correlate with
the incidence of both Ehlers–Danlos syndrome type VII C and
dermatosparaxis in cattle [56]. Ehlers–Danlos syndrome is a
recessively inherited connective-tissue disorder that arises as
a result of incorrectly processed procollagen N-telopeptides
and is characterised by extreme skin fragility, joint laxity and
droopy skin [57]. adamts2 knockout mice seem normal at
birth but soon develop fragile skin, and male mice are infertile
with decreased testicular sperm, suggesting that ADAMTS-2
has important functions both in regulating the formation and
structure of skin and in the maturation of spermatogonia [58].
Despite these abnormalities, a large fraction of both type I N-
propeptides in skin and type II N-propeptides in cartilage are
cleaved in adamts2 knockout mice, indicating the presence
of additional procollagen N-peptidases. ADAMTS-3 has since
been identified as a type II procollagen N-propeptidase,
whose expression is much lower than ADAMTS-2 in skin but
is about 5-fold that of ADAMTS-2 in cartilage [59]. It has been
suggested that the relative expression patterns of ADAMTS-2
and -3 explain the relative sparing of tissues such as cartilage
in dermatosparaxis [59]. ADAMTS-14 has been identified as a
homologue of ADAMTS-2, functioning as the major type I
procollagen N-propeptidase activity in tendon [60].
Von Willebrand factor-cleaving protease: ADAMTS-13
ADAMTS-13 cleaves the large multimeric von Willebrand
factor (vWF) precursor to generate vWF of optimal size for
proper coagulation [20,61,62]. Mutations in ADAMTS-13
correlate with the occurrence of the hereditary form [63], and
autoantibodies against ADAMTS-13 with the sporadic form
[64], of thrombotic thrombocytopenic purpura, a disease in
which the cleavage of vWF is decreased resulting in large
vWF multimers.
Other ADAMTS proteins: ADAMTS-6, -7, -10, -12, -16,
-17, -18 and -19
Functions have not been assigned to this subgroup of
ADAMTS proteins. However, ADAMTS-7, -10 and -12 are
known to be proteolytically active, although ADAMTS-7 does
not cleave aggrecan or versican at the sites characteristic of
the hyalectanase ADAMTS subgroup [17,65,66]. The long
form of ADAMTS-7 contains both O-linked glycosylations and
an N-linked chondroitin sulphate (CS) chain within its mucin-
like domain [17]. The presence of this CS chain is reported to
reduce the affinity of the protein for heparin [17]. Null
mutations of the ADAMTS10 gene have recently been
attributed to a recessive form of Weill–Marchesani syndrome,
whose symptoms include short stature, brachydactyly, joint
stiffness and eye lens abnormalities [67].
Regulation of ADAMTS expression, structure
and activity
Regulation of expression
ADAMTS-1 was initially identified as a novel murine cDNA
expressed in a cachexigenic adenocarcinoma cell line that
could be upregulated by IL-1 [4]. The intravenous admini-
stration of lipopolysaccharide into mice induces expression in
the kidney and heart, suggesting that ADAMTS-1 is an
inflammation-associated gene product [4]. ADAMTS-1, -6
and -9 mRNA levels are upregulated in response to tumour
necrosis factor-α in retinal pigment epithelium-derived cells
[68] and ADAMTS-4 mRNA expression is increased by IL-17
in articular chondrocytes [69], indicating that other ADAMTS
proteins might also be upregulated by inflammatory cytokines.
The induction of ADAMTS-4 mRNA in β-amyloid-treated rat
astrocytes supports an inflammatory-associated role for this
gene [70].
In articular cartilage an upregulation in mRNA level by
transforming growth factor β has been shown for ADAMTS-4
but not ADAMTS-5 [71], indicating that gene expression of
these aggrecanases might be differentially regulated.
Differential regulation of these genes has also been reported
with an immortalised human chondrocyte cell line, in which
IL-1α together with oncostatin M, but not either cytokine
alone, upregulated ADAMTS-4 mRNA, whereas ADAMTS-5
mRNA was upregulated by IL-1α and there was no effect of
oncostatin M [72]. An induction by IL-1α of both ADAMTS-4
and -5 in mouse cartilage explants has been reported [36].
However, studies in human articular cartilage and bovine
nasal cartilage and synovium suggest that the expression of
ADAMTS-4 and -5 mRNA is relatively insensitive to retinoic
acid or IL-1α, despite the marked upregulation of aggre-
canase activity [73-75]. A recent study of ADAMTS-4
suggests that the increase in aggrecanase activity observed
after treatment with IL-1α is mediated, at least in part, through
the upregulation of other enzymes that then process and
activate existing ADAMTS enzyme within the tissue (see also
below) [76].
Post-transcriptional regulation
Post-transcriptional regulation through alternative splicing has
been identified for several of the ADAMTS proteins, including
ADAMTS-6, -7 and -9 [68,77]. Initial reports predicted that
ADAMTS-6 and -7 proteins would terminate after a single C-
terminal TSR [78] and that ADAMTS-9 would terminate after
three C-terminal TSRs [79,80]. However, the full coding
sequences of ADAMTS-6, -7 and -9 are now believed to
encode four C-terminal TSRs followed by a PLAC domain,
seven C-terminal TSRs interrupted by a mucin-like domain
and followed by a PLAC domain, and 14 C-terminal TSRs,
respectively [81] (Fig. 2). In addition, other splice variants of
ADAMTS-6 have been identified that terminate after the pro-
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domain and immediately after the catalytic domain [77]. The
identification of spliced variants of ADAMTS-6, -7 and -9
suggests that splicing might be an important mechanism of
regulation of this family of enzymes in which the ancillary
domains of the proteins are altered. It is worth noting that the full
coding sequences of ADAMTS-16 and -18 are also predicted
to be longer than initially reported [80], each encoding five C-
terminal TSRs followed by a PLAC domain [81].
Present studies of ADAMTS-6 have identified a potential
translational regulatory mechanism for the expression of this
protein [77]. The full 5′ untranslated region of this mRNA
contains multiple upstream ATG initiation codons followed by
very short open reading frames that are predicted to recruit
ribosomes to non-productive sites, thereby reducing the rate
of translation. By switching to a transcript lacking these
upstream ATGs, either by mRNA processing or through the
use of an alternative promoter, protein production could be
increased, a form of regulation that has been implicated in
several diseases [82].
Post-translational regulation
ADAMTS enzymes are synthesised as zymogens that
undergo the constitutive removal of the pro-domain in the
secretory pathway by pro-protein convertases such as furin
(see above). Secreted ADAMTS proteinases can undergo
additional processing at their C-terminal end. Studies of
ADAMTS-1 and -4 have identified cleavages within the
respective spacer domains, and a study of ADAMTS-12
revealed a cleavage within the mucin-like domain that
released the C-terminal TSR quadruplet [83]. For ADAMTS-
4, two such events have been identified so far, one resulting
in the removal of most of the spacer region, the other in the
removal of the spacer region and most of the CRD [9].
Although C-terminal processing of ADAMTS-4 has been
shown to occur through an autocatalytic mechanism [9], cell-
based experiments have suggested that such cleavages are
mediated by MMP [83-85]. A processing pathway in which
the full-length mature enzyme is bound at the cell surface and
cleaved to generate both identified truncated forms by
membrane-type 4-MMP (MT4-MMP, also termed MMP-17)
has been proposed [85]. The processed form retaining the
CRD seems to be maintained at the cell surface by
syndecan-1 through interactions with both CS and heparan
sulphate chains, whereas the shortest form is released into
the medium.
The cleavage of ADAMTS-1 and -4 proteins within the CRD-
spacer region reduces the affinity of both for heparin,
suggesting that the spacer region influences these
interactions [83,84]. These processing events also alter the
activities of these proteins; for example, they reduce the
angioinibitory capacity of ADAMTS-1 and alter the activity of
ADAMTS-4 against aggrecan [83,84]. The processed
ADAMTS-4 is able to cleave aggrecan within the
interglobular domain (IGD) in addition to sites within the CS
attachment region that are also cleaved by the full-length
proteinase [83,84]. Similarly, investigations of ADAMTS-13
proteins revealed that the major epitopes of inhibitory
autoantibodies from patients with thrombotic
thrombocytopenic purpura reside within the CRD-spacer
region and that removal of the CRD-spacer region results in a
marked reduction in vWF cleaving activity [86]. It therefore
seems that the CRD-spacer region influences the activities of
the catalytic domains of the ADAMTS proteinases.
Studies of ADAMTS-4 have given an insight into the influence
of the ancillary domains on the proteinase activities. A recent
study of truncated recombinant forms of ADAMTS-4
indicated that the presence of the CRD was required for
maximal aggrecanase activity, whereas the inclusion of the
spacer region prevented cleavage of aggrecan at the IGD
site [27]. In addition, the presence of the spacer region
prevented the cleavage of non-proteoglycan substrates such
as deglycosylated aggrecan, chemically modified transferrin,
and fibromodulin, an activity that required only the catalytic
and disintegrin-like domains [27].
These data suggest the ADAMTS-4 catalytic domain
possesses a proteolytic activity that is modulated by the
spacer region so that the characteristic non-IGD ‘aggre-
canase’ sites of aggrecan are favoured over the IGD ‘aggre-
canase’ site and non-hyalectan substrates. In addition, the
requirement of the CRD for optimal cleavage of glycosylated
aggrecan compared with its negligible influences on the
cleavage of non-proteoglycan substrates suggests that this
domain promotes hyalectan cleavage by mediating inter-
actions with sulphated glycosaminoglycan, in a similar
manner to that proposed for the activation by heparan
sulphate of growth-factor-receptor signalling [87].
The processing of ADAMTS enzymes is likely to be of
importance in pathologies such as the arthritides, in which
loss of aggrecan seems to be a primary event [88]. The
activity of the full-length ADAMTS-4 seems to be restricted to
cleavages within the CS region of aggrecan, events that
would truncate the proteoglycan but would not be expected
to remove aggrecan from cartilage. However, processing
events removing the spacer region might generate a more
promiscuous and destructive activity capable of dis-
aggregating aggrecan–hyaluronan complexes through IGD
proteolysis, resulting in the loss of aggrecan from the tissue.
Additional processing, removing the CRD, may reduce
activity towards aggrecan in favour of non-proteoglycan
substrates. When considering the role of ADAMTS-4 or other
ADAMTS proteinases in arthritic pathologies it may therefore
be prudent to consider the enzyme form in addition to the
absolute levels of the protein.
Regulation by inhibitors
The most significant endogenous ECM inhibitor of ADAMTS
proteinases to be identified is tissue inhibitor of metallo-
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proteinases-3 (TIMP-3) [89], although other TIMP members
possess a limited inhibitory capacity [90]. TIMP-3 is unique
among the TIMP family in that it binds tightly to, and is found
exclusively within, the ECM [91]. In addition to the TIMP
family, papilin, a protein with homology to the ancillary
domains of ADAMTS proteins, is a non-competitive inhibitor
of ADAMTS-2 [92]. Recently, the C-terminal portion of
fibronectin has also been reported as a potent inhibitor of
ADAMTS-4 [93].
Roles of the ADAMTS family in connective
tissues
There have been few comprehensive studies of ADAMTS in
connective tissues. However, the expression of the entire
ADAMTS subfamily was recently investigated in normal and
OA cartilage [1]. This study indicated that, with the exception
of ADAMTS-7 and -8, normal cartilage expressed the entire
ADAMTS subfamily. The most highly expressed of the
ADAMTS proteinase mRNAs were those for ADAMTS-1, -5,
-6, -15, -18 and -19, and observed differences between
normal and late-stage OA cartilage included the lower
expression of ‘hyalectanase’ ADAMTS proteinases
(ADAMTS-1, -5, -9 and -15) and a higher expression of
procollagen peptidases (ADAMTS-2 and -14). Furthermore,
two ADAMTS members of unknown function (ADAMTS-12
and -16) were more highly expressed in OA. Although the
levels of hyalectanases were not increased in late-stage OA
this result does not preclude a role for this proteinase in the
early stages of OA. In a comparison of normal and chronic
painful tendon by this group (GC Jones, AN Corps, CJ
Pennington, IM Clark, DR Edwards, MM Bradley, BC
Hazleman, GP Riley, unpublished work), the expression of all
19 ADAMTS genes was detected. A lower expression level of
ADAMTS-5 and higher levels of ADAMTS-2, -12, -14 and -17
were observed in chronic painful tendon. These data suggest
that many members of the ADAMTS subfamily might possess
important roles in both the homeostasis and pathology of
connective tissues and are worthy of further investigation.
Conclusions
The ADAMTS enzymes are a group of secreted proteinases
possessing a conserved N-terminal domain architecture
followed by a variable C terminus. The phylogenetic
relationship of these proteinases broadly defines four
subdivisions, which also seem to discriminate protein
activities. Evidence suggests that the synthesis of these
proteinases is regulated at the level of both expression and
translation and that their structures and activities are
regulated through mRNA splicing and post-translationally
through protein processing and endogenous inhibitors. The
cleavage state of individual ADAMTS proteinases seems to
be of importance, because ancillary domains (particularly the
CRD and spacer region) seem to modulate the specificity of
their activities, an event that might be of significance in
arthritis [75]. The complex nature of the regulation of these
proteinases implies that a precise control of their activities is
required for the maintenance of homeostasis. A broad
spectrum of ADAMTS proteinases are expressed in both
cartilage and tendon, which suggests that multiple ADAMTS
proteinases are important in the homeostasis of these
tissues.
In conclusion, the ADAMTS proteins are complex, multi-
domain, proteinases whose synthesis and activity are
subjected to multiple levels of regulation and which are
widely expressed in connective tissues, in both health and
pathology.
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